{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:14:14Z","timestamp":1789902854688,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10072-025-08411-4","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T02:59:48Z","timestamp":1755745188000},"page":"5643-5655","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["From diabetes to dopamine: Evaluating the disease-modifying potential of GLP-1 receptor agonists in Parkinson\u2019s disease. A systematic review and meta-analysis of placebo-controlled trials"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8445-778X","authenticated-orcid":false,"given":"Ahmed Samy","family":"Badran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ibrahim","family":"Gbreel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"8411_CR1","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/mds.25945","volume":"29","author":"T Pringsheim","year":"2014","unstructured":"Pringsheim T, Jette N, Frolkis A, Steeves TDL (2014) The prevalence of Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord 29:1583\u20131590. https:\/\/doi.org\/10.1002\/mds.25945","journal-title":"Mov Disord"},{"key":"8411_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS (2020) Diagnosis and treatment of Parkinson disease. JAMA 323:548. https:\/\/doi.org\/10.1001\/jama.2019.22360","journal-title":"JAMA"},{"key":"8411_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2003.tb07458.x","volume":"991","author":"S Fahn","year":"2003","unstructured":"Fahn S (2003) Description of Parkinson\u2019s disease as a clinical syndrome. Ann N Y Acad Sci 991:1\u201314. https:\/\/doi.org\/10.1111\/j.1749-6632.2003.tb07458.x","journal-title":"Ann N Y Acad Sci"},{"key":"8411_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/jcpt.13230","volume":"45","author":"S Cornell","year":"2020","unstructured":"Cornell S (2020) A review of GLP-1 receptor agonists in type 2 diabetes: a focus on the mechanism of action of once\u2010weekly agents. J Clin Pharm Ther 45:17\u201327. https:\/\/doi.org\/10.1111\/jcpt.13230","journal-title":"J Clin Pharm Ther"},{"key":"8411_CR5","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","volume":"24","author":"SP Yun","year":"2018","unstructured":"Yun SP, Kam T-I, Panicker N et al (2018) Block of A1 astrocyte conversion by microglia is neuroprotective in models of parkinson\u2019s disease. Nat Med 24:931\u2013938. https:\/\/doi.org\/10.1038\/s41591-018-0051-5","journal-title":"Nat Med"},{"key":"8411_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12760","author":"F Bassil","year":"2022","unstructured":"Bassil F, Delamarre A, Canron M et al (2022) Impaired brain insulin signalling in Parkinson\u2019s disease. Neuropathol Appl Neurobiol. https:\/\/doi.org\/10.1111\/nan.12760","journal-title":"Neuropathol Appl Neurobiol"},{"key":"8411_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","volume":"303","author":"W Liu","year":"2015","unstructured":"Liu W, Jalewa J, Sharma M et al (2015) Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of parkinson\u2019s disease. Neuroscience 303:42\u201350. https:\/\/doi.org\/10.1016\/j.neuroscience.2015.06.054","journal-title":"Neuroscience"},{"key":"8411_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052687","volume":"23","author":"M Michailidis","year":"2022","unstructured":"Michailidis M, Moraitou D, Tata DA et al (2022) Alzheimer\u2019s disease as type 3 diabetes: common pathophysiological mechanisms between Alzheimer\u2019s disease and type 2 diabetes. Int J Mol Sci 23:2687. https:\/\/doi.org\/10.3390\/ijms23052687","journal-title":"Int J Mol Sci"},{"key":"8411_CR9","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1002\/mds.26734","volume":"31","author":"P Svenningsson","year":"2016","unstructured":"Svenningsson P, Wirdefeldt K, Yin L et al (2016) Reduced incidence of Parkinson\u2019s disease after dipeptidyl peptidase-4 inhibitors-a nationwide case-control study. Mov Disord 31:1422\u20131423. https:\/\/doi.org\/10.1002\/mds.26734","journal-title":"Mov Disord"},{"key":"8411_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/mds.29298","volume":"38","author":"PW Cullinane","year":"2023","unstructured":"Cullinane PW, de Pablo Fernandez E, K\u00f6nig A et al (2023) Type 2 diabetes and Parkinson\u2019s disease: a focused review of current concepts. Mov Disord 38:162\u2013177. https:\/\/doi.org\/10.1002\/mds.29298","journal-title":"Mov Disord"},{"key":"8411_CR11","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/brain\/awaa262","volume":"143","author":"R Brauer","year":"2020","unstructured":"Brauer R, Wei L, Ma T et al (2020) Diabetes medications and risk of Parkinson\u2019s disease: a cohort study of patients with diabetes. Brain 143:3067\u20133076. https:\/\/doi.org\/10.1093\/brain\/awaa262","journal-title":"Brain"},{"key":"8411_CR12","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/mds.29992","volume":"39","author":"H Tang","year":"2024","unstructured":"Tang H, Lu Y, Okun MS et al (2024) Glucagon-like peptide-1 receptor agonists and risk of parkinson\u2019s disease in patients with type 2 diabetes: a population-based cohort study. Mov Disord 39:1960\u20131970. https:\/\/doi.org\/10.1002\/mds.29992","journal-title":"Mov Disord"},{"key":"8411_CR13","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1172\/JCI68295","volume":"123","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z et al (2013) Exenatide and the treatment of patients with Parkinson\u2019s disease. J Clin Invest 123:2730\u20132736. https:\/\/doi.org\/10.1172\/JCI68295","journal-title":"J Clin Invest"},{"key":"8411_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","volume":"23","author":"A McGarry","year":"2024","unstructured":"McGarry A, Rosanbalm S, Leinonen M et al (2024) Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 23:37\u201345. https:\/\/doi.org\/10.1016\/S1474-4422(23)00378-2","journal-title":"Lancet Neurol"},{"key":"8411_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02808-3","author":"N Vijiaratnam","year":"2025","unstructured":"Vijiaratnam N, Girges C, Auld G et al (2025) Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(24)02808-3","journal-title":"Lancet"},{"key":"8411_CR16","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J et al (2019) Cochrane handbook for systematic reviews of interventions. John Wiley & Sons","DOI":"10.1002\/9781119536604"},{"key":"8411_CR17","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"8411_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5195\/jmla.2017.111","volume":"105","author":"WM Bramer","year":"2017","unstructured":"Bramer WM, Milic J, Mast F (2017) Reviewing retrieved references for inclusion in systematic reviews using endnote. J Med Libr Assoc 105:84\u201387. https:\/\/doi.org\/10.5195\/jmla.2017.111","journal-title":"J Med Libr Assoc"},{"key":"8411_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5:1\u201310","journal-title":"Syst Rev"},{"key":"8411_CR20","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"8411_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 14:135. https:\/\/doi.org\/10.1186\/1471-2288-14-135","journal-title":"BMC Med Res Methodol"},{"key":"8411_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13. https:\/\/doi.org\/10.1186\/1471-2288-5-13","journal-title":"BMC Med Res Methodol"},{"key":"8411_CR23","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS et al (2017) Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390:1664\u20131675. https:\/\/doi.org\/10.1016\/S0140-6736(17)31585-4","journal-title":"Lancet"},{"key":"8411_CR24","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/nejmoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner WG, Remy P, Giordana C et al (2024) Trial of lixisenatide in early Parkinson\u2019s disease. N Engl J Med 390:1176\u20131185. https:\/\/doi.org\/10.1056\/nejmoa2312323","journal-title":"N Engl J Med"},{"key":"8411_CR25","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4212371","volume-title":"A phase II, randomized, double-blinded, placebo-controlled trial of liraglutide in Parkinson\u2019s disease","author":"E Hogg","year":"2022","unstructured":"Hogg E, Wu T, Bresee C et al (2022) A phase II, randomized, double-blinded, placebo-controlled trial of liraglutide in parkinson\u2019s disease. Randomized, Double-Blinded, Placebo-Controlled Trial Liraglutide Park Dis"},{"key":"8411_CR26","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JPD-140364","volume":"4","author":"I Aviles-Olmos","year":"2015","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z et al (2015) Motor and cognitive advantages persist 12 months after exenatide exposure in parkinson\u2019s disease. J Parkinsons Dis 4:337\u2013344. https:\/\/doi.org\/10.3233\/JPD-140364","journal-title":"J Parkinsons Dis"},{"key":"8411_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70075","author":"M Gamborg","year":"2025","unstructured":"Gamborg M, Grand MK, Arvedsen J et al (2025) GLP-1 agonists as potential neuromodulators in development of Parkinson\u2019s disease: a nationwide cohort study. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.70075","journal-title":"Eur J Neurol"},{"key":"8411_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-03932-3","author":"M Messak","year":"2025","unstructured":"Messak M, Abdelmageed A, Senbel AA et al (2025) Efficacy and safety of GLP-1 agonists in parkinson\u2019s disease: a systematic review and meta-analysis of randomized controlled trials. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-025-03932-3","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"8411_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107220","volume":"130","author":"MB de Albuquerque","year":"2025","unstructured":"de Albuquerque MB, Nunes LEDB, de Oliveira Maldonado JV et al (2025) GLP-1 receptor agonists for Parkinson\u2019s disease: an updated meta-analysis. Parkinsonism Relat Disord 130:107220. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.107220","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08411-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08411-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08411-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:02:31Z","timestamp":1760983351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08411-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["8411"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08411-4","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This meta-analysis was based on previously published studies, and ethical approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}